Humaid Al-Shamsi, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared Burjeel Cancer Institute | BCI’s post on LinkedIn, adding:
“The first center globally.
Because we ALWAYS put our patients first, we go further.
Innovation is not about being first—it is about making a difference for every patient we serve.
Today, we are proud to lead the way by bringing groundbreaking cancer treatments to patients before anyone else, turning scientific advances into real hope.
Our commitment remains simple: patients first, always.”
Quoting Burjeel Cancer Institute’s post:
“Burjeel Cancer Institute has marked a global first by treating an advanced breast cancer patient with Etcamah (camizestrant), a novel precision therapy targeting an ESR1 mutation. Guided by ctDNA testing, this approach enables clinicians to detect treatment resistance earlier and personalize care before visible disease progression.
This milestone highlights the strength of the UAE’s healthcare ecosystem and its commitment to bringing world-class cancer innovations closer to patients.”
More posts featuring Humaid Al-Shamsi.
